Clinical Trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07524530 2026-04-16

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

98 enrolled

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07192237 2026-04-15

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07529405 2026-04-14

CurbMF

386 enrolled

Mycosis Fungoides

NCT07526597 2026-04-13

STOP-CLL-DCT

45 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07194980 2026-04-08

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07508995 2026-04-03

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07507318 2026-04-02

DEL-MRD-CHID

69 enrolled

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07505849 2026-04-01

ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

100 enrolled

Lymphoma, Follicular

NCT07502872 2026-03-31

TPG

30 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07494565 2026-03-27

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

60 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07341191 2026-03-25

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Recurrence, Lymphoma, Mantle-Cell

NCT07292272 2026-03-23

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

LymphoidOther hematologic neoplasmPlasma cell

180 enrolled

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Hodgkin Disease

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Lymphoma, B-Cell

NCT07164469 2026-03-11

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

100 enrolled

Hodgkin Disease

NCT07464210 2026-03-11

Nemtabrutinib, Bortezomib, and Rituximab for WM

19 enrolled

Waldenstrom Macroglobulinemia

NCT07178912 2026-03-09

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07457177 2026-03-09

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Lymphoma, Extranodal NK-T-Cell

NCT07453095 2026-03-05

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05565105 2026-03-03

CD34+ Transplants for Leukemia and Lymphoma

100 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07313852 2026-02-04

A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

26 enrolled

Burkitt Lymphoma

NCT07385989 2026-02-04

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT07180771 2026-01-28

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

44 enrolled

Lymphoma, T-Cell, Peripheral

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07360288 2026-01-22

TC011_FL_201

Lymphoma, Follicular

NCT07024706 2026-01-21

MAVRiC

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

23 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07301424 2025-12-24

Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

80 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07299149 2025-12-23

ZGR in TN FL

34 enrolled

Lymphoma, Follicular

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

25 enrolled

Lymphoma, T-Cell

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

31 enrolled

Lymphoma, T-Cell, Peripheral

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

39 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT07276737 2025-12-11

Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma

37 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT07261163 2025-12-03

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT07259122 2025-12-02

ZBR in WM

43 enrolled

Waldenstrom Macroglobulinemia

NCT06547866 2025-11-26

WAZABI

102 enrolled

Waldenstrom Macroglobulinemia

NCT07244380 2025-11-24

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

38 enrolled

Lymphoma

NCT07227584 2025-11-12

ALL Backbone in AYAs

67 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07207785 2025-10-06

FIL_PUMA

56 enrolled

Lymphoma, Mantle-Cell

NCT07206264 2025-10-03

ADAPT-MCL

45 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT06570915 2025-10-01

T-ALL-2024

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07197307 2025-09-29

CLEAR

120 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT07191249 2025-09-24

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

30 enrolled

Lymphoma, Follicular

NCT07144657 2025-08-27

GastricMALToma

Lymphoma, B-Cell, Marginal Zone

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06930105 2025-08-06

Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL

45 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

35 enrolled